Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009

There are approximately 44,000 cases of human papillomavirus–associated (HPV-associated) cancer each year in the United States, most commonly caused by HPV types 16 and 18. Prophylactic vaccines successfully prevent healthy people from acquiring HPV infections via HPV-specific antibodies. In order t...

Full description

Bibliographic Details
Main Authors: Samuel T. Pellom, Claire Smalley Rumfield, Y. Maurice Morillon II, Nicholas Roller, Lisa K. Poppe, Douglas E. Brough, Helen Sabzevari, Jeffrey Schlom, Caroline Jochems
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-04-01
Series:JCI Insight
Subjects:
Immunology
Oncology
Online Access:https://doi.org/10.1172/jci.insight.141912

Internet

https://doi.org/10.1172/jci.insight.141912

Similar Items